OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in…
OXFORD, England, Nov. 17, 2025 /PRNewswire/ -- Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it…
Local Clinic Offers Newly Approved Monotherapy Option for Treatment-Resistant Depression - No Daily Antidepressant Required SAN LUIS OBISPO, CA /…
"The federal hemp crackdown has created long overdue pharmaceutical clarity. MMJ is now the company advancing a fully compliant cannabinoid…
FORT PIERCE, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Caring Brands, Inc. (“Caring Brands” or the “Company”), a wellness consumer…
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular…
–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study…
MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage…
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA…
Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 /…